Table 1

Demographic and plasma vascular endothelial growth factor (VEGF) data obtained from patients with exudative age-related macular degeneration

ARMDBaseline7 days4 weeksp Value*
Age (SEM)N (Males n)Mean (SEM) VEGF pg/mlMedian25th/75th Percentilen (Males n)Mean (SEM) VEGF pg/mlMedian25th/75th Percentilen (Males n)Mean (SEM) VEGF pg/mlMedian25th/75th Percentile
Bevacizumab77.7 (3.0)10 (3)89.7 (33.7)50.037.0/98.29 (3)25.1 (3.5)23.016.0/36.09 (3)22.8 (4.1)25.011.5/34.00.004
Ranibizumab79.9 (2.6)10 (4)91.3 (18.9)77.048.5/126.310 (4)135.5 (42.2)117.538.5/162.38 (4)77.1 (16.5)55.045.2/99.20.607
Pegaptanib777 (2.0)10 (3)105.5 (41.7)46.521.5/174.810 (3)139.7 (39.6)94.062.5/191.010 (3)151.7 (66.1)50.024.0/279.50.820
  • *p Values for comparison of VEGF levels using Friedman test. p Values of less than 0.05 were considered to indicate statistical significance.

  • ARMD, age-related macular degeneration; SEM, standard error mean.